Compare Lumen Technologies Inc (LUMN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Sanofi SA — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16.6× Lumen Technologies Inc's market cap, and Sanofi SA pays a 6.01% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Sanofi SA for 94 Days on average.
| LUMN | SNY | |
|---|---|---|
Market Cap | $5.73B | $95.18B |
Volume | 17,079,799 | 2,995,646 |
Sector | Media | Health |
52-Week High | $11.83 | $52.34 |
52-Week Low | $5.53 | $39.51 |
Typical Hold Time | 40 Days | 94 Days |
Enterprise Value | $17.35B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.56, down 5.92% on the day, reflecting ongoing investor caution amid weak profitability and high debt. The stock shows a bearish technical trend with key support at $5.00, while fundamentals reveal declining revenue, negative net income margins, and a challenging turnaround effort. Recent news highlights a Nasdaq listing move and AI-focused networking initiatives, but legacy telecom declines persist.
Outlook remains speculative with high execution risk; the company's deep value (P/S 0.47) and AI growth potential contrast with consistent losses and substantial leverage. Analyst consensus is Reduce, with 60.7% Hold ratings, signaling limited near-term confidence despite strategic pivots.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
